

REMARKS

Claims 1-4 are pending in the application. In the Office Action of June 22, 2006, the Examiner has divided the claims into two (2) groups: Group I (claims 1 and 2), drawn to methods of treating a human patient susceptible to or exhibiting symptoms of invasive cancer and to methods for treating a human patient susceptible to or exhibiting symptoms of metastatic tumors, comprising administering a composition comprising L-histidine or quisqualic acid and Group II (claims 3 and 4), drawn to methods of treating a human patient where angiogenesis inhibition is indicated and to methods of treating a human patient wherein treatment with endostatin has been indicated, comprising administering a composition comprising L-histidine or quisqualic acid.

The presently claimed invention is generally directed to treatments for cancer and treatments using angiogenesis inhibitors. Endostatin is widely known as an inhibitor of angiogenesis. Applicants have for the first time demonstrated that the mechanism by which endostatin inhibits angiogenesis in the present application. Accordingly, Applicants assert that a molecule that mimics the activity of endostatin would logically also inhibit angiogenesis. It is also widely known that angiogenesis inhibitors also inhibit the growth of the tumors. Therefore, it is believed that all of the inventive methods of treatments for invasive cancer, metastatic tumors, angiogenesis inhibition, and endostatin treatment are closely related. Applicants submit that the methods divided into Groups I and II are closely related each other to form a single inventive method to detect the interaction of samples.

Further, Applicants submit that there is not an undue burden placed upon the Examiner to search and consider all of the closely related claims. Accordingly, all of the claims should be joined and examined together.

However, in order to be responsive to the outstanding Restriction Requirement, Applicants provisionally elect to prosecute the subject matter of Group II (claims 3 and 4), drawn to methods of treating a human patient where angiogenesis inhibition is indicated and to methods of treating a human patient wherein treatment with endostatin has been indicated, comprising administering a composition comprising L-histidine or quisqualic acid, for prosecution on the merits, with traverse. Applicants specifically preserve the right to prosecute the non-elected claims.

Accordingly, early examination on the merits is respectfully requested.

The Commissioner is authorized to charge Deposit Account 502486 for any fees due to secure entry of this amendment to the extent necessary.

July 24, 2006

Respectfully submitted,

/Joseph Hyosuk Kim/
Joseph Hyosuk Kim, Ph. D.
Registration No. 41,425

JHK Law
P.O. Box 1078
La Canada, CA 91012-1078
Telephone: 818-249-8177
Facsimile: 818-249-8277